| Current Price | $479.02 | Mkt Cap | $14.1B |
|---|---|---|---|
| Open | $471.78 | P/E Ratio | 0.00 |
| Prev. Close | $479.02 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $469.71 - $479.41 | Volume | 142,969 |
| 52-Wk Range | $344.63 - $607.54 | Avg. Daily Vol. | 179,630 |
The Company manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets with products and systems used to separate chemical and biological materials, and to identify analyze and purify their components.
| Current Price | $479.02 | Mkt Cap | $14.1B |
|---|---|---|---|
| Open | $471.78 | P/E Ratio | 0.00 |
| Prev. Close | $479.02 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $469.71 - $479.41 | Volume | 142,969 |
| 52-Wk Range | $344.63 - $607.54 | Avg. Daily Vol. | 179,630 |
The best Bull and Bear pitches based on recency and number of recommendations.
This is one of my STARZ.Here is the thought process on this STAR: a) Divided rate over Zerob) 3 Year Beta between -5 & +3c) 15% + Insider ownershipd) No greater than -50% Growth rate for the last 3 years (tought= last couple of years so goo that… More
Cut in earnings leaves the stock worth $50-60. This one still has further to fall.
Read the most recent pitches from players about BIO.
Recs
TMFjimhalley
(< 20)
Submitted: 8/4/2021 12:22:52 PM :
Start Price:
$755.82
NYSE:BIO Score:
-30.04
Impressive streak of earnings growth and strong total return. The stock is priced attractively, considering its earnings growth.
Recs
RowdyCat
(52.84)
Submitted: 10/24/2017 4:58:22 PM :
Start Price:
$222.31
NYSE:BIO Score:
+54.48
Bio-Rad supplies molecular biology and biochemistry laboratories across the country with everyday essentials. Without Bio-Rad, much of the work conducted could not be completed.
Recs
TMFDeej
(85.94)
Submitted: 12/1/2016 3:52:18 PM :
Start Price:
$174.29
NYSE:BIO Score:
+86.76
Here's an interesting article on this week's Robin Hood Investor Conference that includes summaries on some of the presenters best ideas. The one that I found most interesting was from Keith Meister ofCorvex Capital:
Meister, an activist investor and a former Carl Icahn lieutenant, gave Bio-Rad Laboratories (BIO) as a long idea. He noted that it’s cheap with no analyst coverage besides Jefferies and no hedge fund ownership. The company has been implementing a new SAP system which has been costing them at the moment. Right now, the company is under-earning, trading at 7-times EBITDA versus peers trading at 14-times. He thinks the company is trading at half its intrinsic value.
Stock picks from inside this week's exclusive hedge fund conference
http://sports.yahoo.com/news/stock-picks-from-inside-this-weeks-exclusive-hedge-fund-conference-224210916.html
Jason
No positin in any company mentioned but DIS
Find the members with the highest scoring picks in BIO.
goldenginkgo (64.21) Score: +393.33
The Score Leader is the player with the highest score across all their picks in BIO.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| goldenginkgo | 64.21 | 5/10/2007 |
|
NS | $69.95 | +579.74% | +186.41% | +393.33 | 0 Comment | |
| looanthony | < 20 | 3/12/2007 |
|
3W | $69.14 | +587.71% | +208.68% | +379.03 | 1 Comment | |
| gingerlade | 48.08 | 4/11/2007 |
|
3M | $70.39 | +575.49% | +198.10% | +377.39 | 0 Comment | |
| wunderdawg | 86.57 | 3/8/2007 |
|
5Y | $69.51 | +584.05% | +208.05% | +375.99 | 0 Comment | |
| Bflatminor7th | 21.95 | 3/28/2007 |
|
3Y | $70.10 | +578.29% | +203.72% | +374.57 | 0 Comment | |
| jiminica | 80.15 | 3/5/2007 |
|
NS | $69.36 | +585.52% | +211.70% | +373.83 | 0 Comment | |
| OSUChad | 95.74 | 3/5/2007 |
|
1Y | $69.68 | +582.38% | +212.62% | +369.76 | 0 Comment | |
| jabs0 | 94.91 | 3/7/2007 |
|
NS | $70.16 | +577.71% | +209.65% | +368.05 | 0 Comment | |
| Jcirus | < 20 | 3/5/2007 |
|
5Y | $69.91 | +580.13% | +214.25% | +365.88 | 0 Comment | |
| tmgllgn | < 20 | 3/5/2007 |
|
3Y | $69.91 | +580.13% | +214.25% | +365.88 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
